CD34 and acute myeloid leukemia: In addition to their report, we found that GSK-J4 demonstrated effective inhibition of cell survival and cell-cycle progression in Kasumi-1, an AML cell line with t(8;21) translocation, and KG-1/KG-1a, two primitive myeloid leukemic cell lines with high CD34 expression levels.